Relyea Zuckerberg Hanson LLC Acquires 437 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Relyea Zuckerberg Hanson LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 3,007 shares of the biopharmaceutical company’s stock after purchasing an additional 437 shares during the quarter. Relyea Zuckerberg Hanson LLC’s holdings in Gilead Sciences were worth $278,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Massachusetts Financial Services Co. MA lifted its position in shares of Gilead Sciences by 0.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after buying an additional 522 shares during the last quarter. Seven Eight Capital LP acquired a new stake in Gilead Sciences in the 2nd quarter worth approximately $525,000. Kendall Capital Management boosted its position in Gilead Sciences by 102.6% during the second quarter. Kendall Capital Management now owns 7,317 shares of the biopharmaceutical company’s stock worth $502,000 after purchasing an additional 3,705 shares during the period. MQS Management LLC grew its holdings in Gilead Sciences by 33.9% during the second quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 1,157 shares during the last quarter. Finally, Ieq Capital LLC raised its position in shares of Gilead Sciences by 3.7% in the second quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company’s stock valued at $4,749,000 after purchasing an additional 2,453 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

GILD stock opened at $91.84 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The business’s 50 day moving average is $91.85 and its 200-day moving average is $83.81. The firm has a market cap of $114.46 billion, a P/E ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.29 earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 in the last ninety days. Insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Bank of America reaffirmed a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wells Fargo & Company boosted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group raised their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $84.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.